From Herceptin to Rozlytrek: how cancer drugs are getting more personalized
September 25, 2019 | Disease
In August 2019, the US FDA approved Roche’s Rozlytrek (entrectinib) for cancer patients whose solid tumors harbor a particular genetic mutation called NTRK. The approval comes more than 20 years after the very first ‘targeted’ breast cancer therapy reached the market – Genentech (now Roche)’s Herceptin (trastuzumab).
The two drugs illustrate how cancer therapies have evolved to treat ever more narrowly-defined groups of patients. Herceptin helps the approximately 20% of breast cancer patients whose tumors over-express the HER2 protein, which can accelerate cancer cell growth. Rozlytrek is only likely to help 2% of breast cancer patients – those whose neurotrophic tyrosine receptor kinase genes have fused with other proteins to cause unwanted cell proliferation. It is the third FDA-approved “tissue agnostic” cancer therapy – one defined by tumors’ genetic signature, not by their location in the body.
Herceptin has been a huge success, and multiple copycat biosimilar versions are now available, both in Europe and the US. Rozlytrek’s success will be spread across a far wider range of cancer types – including colorectal, neuro-endocrine, non-small cell lung, pancreatic and thyroid cancers. The drug also received a tissue-specific designation, for the approximately 2% of metastatic non-small cell lung cancers that are positive for the ROS1 gene, which codes for a tyrosine kinase.
Rozlytrek will not enjoy the same first-mover advantage that Roche had with Herceptin. Bayer’s Vitrakvi (larotrectinib), approved by the FDA late 2018, also helps patients with NTRK-positive solid tumors, including breast tumors, setting up a head-long battle between the two companies. (Vitrakvi received a positive opinion from the EU’s CHMP in July 2019.)
Roche showed the strength of its intent to gain market share from its rival by pricing Rozlytrek at almost half the level of Vitrakvi – $17,000 per month, versus $33,000 for Vitrakvi. The drugs are not identical: trials showed different overall response rates, though the patient populations were different, making it tricky to draw conclusions. Yet Roche is in fact fighting two battles, in parallel with the drug’s two approved indications. One battle is
against Bayer (which acquired full rights to Vitrakvi from partner Loxo Oncology after Eli Lilly paid $8 billion to acquire Loxo in January 2019) and the other is against Pfizer, whose Xalkori is approved in the same ROS1-positive NSCLC setting as Rozlytrek.
Roche may have an advantage over both its rivals. For one thing, it has the most to lose: oncology makes up about half its total sales. As generics hit several of its blockbusters, the group has spent many billions buying oncology-focused data to improve diagnosis, trial recruitment and drug development. It also has a diagnostics business. Diagnostic testing is increasingly important to determine which patients can benefit from these increasingly narrowly-targeted medicines. Roche plans to launch a companion diagnostic test for Rozlytrek via its Foundation Medicine subsidiary; once it does, this may provide Roche with another weapon against its competitors. Finding patients with NTRK fusion genes isn’t easy, since these rare mutations are not routinely tested for. If Roche can find a way to incentivize more physicians to use its test – a big if – they are then more likely to use the associated drug.
Bayer, meanwhile, is embroiled in litigation within its agri-division (where it owns seed-maker Monsanto) accusing it of indirectly causing cancer via its Roundup weed-killer product. This may not help the company’s image as a provider of cancer therapies.
Both it and Roche may face another competitor if Turning Point Therapeutics’ repotrectinib gets through its current Phase 1/2 trial in patients with advanced TRK-positive solid tumors and ROS-1 positive NSCLC.
Breast cancer is now thought of as survivable in many cases, given a wide range of effective treatments, including Herceptin. But there are hurdles to surmount before even approved drugs like Rozyltrek are routinely available in many markets. The UK’s NICE is likely to push back on price, even before practicalities such as diagnostic testing have been sorted out.
And while battles are fought for these ever-thinner slices of the oncology market, there remains an important unmet need in the 10-20% of breast cancers that are designated ‘triple negative’ – meaning they are not fuelled by estrogen or progesterone, or by the HER2 protein that Herceptin goes after. There are medicines available for this category – including PARP inhibitors like Lynparza (olaparib) for patients with BRCA1 or BRCA2 mutations, or immune-therapy Tecentriq (atezolizumab) which targets the PD-L1 protein that helps cancer cells hide from the immune system. But they don’t help everyone.
And the first tissue-agnostic medicine to be approved, Merck’s top-selling immuno-therapy drug Keytruda (pembrolizumab), recently failed to improve overall survival compared to chemotherapy as second- or third-line monotherapy treatment in patients with metastatic triple negative breast cancer.
Breast cancer is one of the few cancer-types for which Keytruda is not approved
Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest
Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK
Breast Cancer: HR+/Her2 Forecast and Market Analysis to 2024
Breast Cancer Diagnostic and Treatment Devices
- November, 13 2019
- September, 02 2019
- August, 11 2019